Two novel antibiotics show promise for TB patients with fewer side effects: Lancet

GERMAN researchers have developed two novel antibiotics that have shown promise for millions of patients with tuberculosis (TB), leading to lesser side effects than the currently available treatments.

- 

The drugs, sutezolid, and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to the currently used linezolid, with the potential to replace this current cornerstone in the treatment of drug-resistant TB.

Two international clinical studies on the antibiotics published in two peer-reviewed articles in the journal The Lancet Infectious Diseases showed that both sutezolid and delpazolid are safe, effective, and potential alternatives to linezolid in the treatment of TB.